US Edition
News from Clinical Trials Arena
If you want to know if Clinical Trials Arena is credible or reliable, look no further. We rank Clinical Trials Arena as Unknown factuality. Find out more about our methodology here.
Information about Clinical Trials Arena
Where is Clinical Trials Arena located?Clinical Trials Arena's WebsiteMedia Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Clinical Trials Arena News
World Health Organization · GenevaMembers of the World Health Organization voted emphatically in favour of a potentially groundbreaking global treaty on improving pandemic preparedness at the World Health Assembly on Monday.See the Story
World Health Organization members vote in favour of global pandemic agreement
37% Left coverage: 126 sources
Taiwan · TaiwanTAIPEI, May 21, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare diseases, today announced positive results from its Phase 1/2a randomized, double-blind, placebo-controlled, first-in-patient clinical…See the Story
AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients
59% Center coverage: 32 sources
FDAFive-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66%…See the Story
Astellas and Pfizer's XTANDI™ (Enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
62% Center coverage: 26 sources
